Neurogene Inc (NGNE)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$23.95

+1.77 (+7.98%)

Market Cap: $443.85M

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

59%(23/39)

Avg Surprise

-172.39%

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-1.42

Range$-1.46 - $-1.36

4 analysts

EPS Revisions

30d

EPS Estimate DriftChange to current

90d ago$-1.30-9.2%

60d ago$-1.31-8.7%

30d ago$-1.27-11.4%

7d ago$-1.27-11.4%

Current$-1.42

Revenue Consensus

Range$0 - $0

7 analysts

Period ending Dec 31, 2026

EPS Consensus$-1.59

Range$-1.83 - $-1.38

5 analysts

Revenue Consensus

Range$0 - $0

7 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-1.59	$-1.83 - $-1.38	-	-	5	-	-
Sep 30, 2026Sep 26EST	-	$-1.42	$-1.46 - $-1.36	-	-	4	3 3 30d	-
Jun 30, 2026Jun 26 Reported Aug 11, 2026Reported Aug 11	$-1.53	$-1.40	$-1.44 - $-1.30	-9.29%	Miss	2	1 0 30d	-45.7%
Mar 31, 2026Mar 26 Reported May 12, 2026Reported May 12	$-1.39	$-1.27	$-1.68 - $-1.00	-9.05%	Miss	6	3 1 30d	-28.4%
Dec 31, 2025Dec 25 Reported Mar 24, 2026Reported Mar 24	$-1.13	$-1.24	$-1.64 - $-1.01	+8.87%	Beat	4	No revisions (30d)	-14.1%
Sep 30, 2025Sep 25 Reported Nov 13, 2025Reported Nov 13	$-0.99	$-1.09	$-1.09 - $-1.09	+9.17%	Beat	1	No revisions (30d)	+16.8%
Jun 30, 2025Jun 25 Reported Aug 11, 2025Reported Aug 11	$-1.05	$-1.16	$-1.16 - $-1.16	+9.48%	Beat	1	No revisions (30d)	+3.7%
Mar 31, 2025Mar 25 Reported May 9, 2025Reported May 9	$-1.08	$-1.12	$-1.12 - $-1.12	+3.57%	Beat	1	No revisions (30d)	-8.0%
Dec 31, 2024Dec 24 Reported Mar 24, 2025Reported Mar 24	$-0.99	$-1.13	$-1.31 - $-1.03	+12.39%	Beat	6	1 1 30d	+34.4%
Sep 30, 2024Sep 24 Reported Nov 18, 2024Reported Nov 18	$-1.19	$-1.22	$-1.34 - $-1.15	+2.46%	Beat	6	No revisions (30d)	-191.9%
Jun 30, 2024Jun 24 Reported Aug 9, 2024Reported Aug 9	$-1.09	$-1.03	-	-5.83%	Miss	-	-	-2625.0%
Mar 31, 2024Mar 24 Reported May 10, 2024Reported May 10	$-1.00	$-0.95	-	-5.26%	Miss	-	-	-284.6%
Dec 31, 2023Dec 23 Reported Mar 26, 2024Reported Mar 26	$-1.51	$-1.17	-	-29.06%	Miss	3	No revisions (30d)	-529.2%
Sep 30, 2023Sep 23 Reported Nov 14, 2023Reported Nov 14	$-0.41	$-0.03	$-0.03 - $-0.03	-1259.00%	Miss	0	No revisions (30d)	-69.9%
Jun 30, 2023Jun 23 Reported Aug 10, 2023Reported Aug 10	$-0.04	$-0.04	$-0.04 - $-0.04	+0.00%	Beat	0	No revisions (30d)	+85.7%
Mar 31, 2023Mar 23 Reported May 10, 2023Reported May 10	$-0.26	$-0.22	-	-18.18%	Miss	-	-	+7.1%
Dec 31, 2022Dec 22 Reported Mar 29, 2023Reported Mar 29	$-0.24	$-0.19	-	-26.32%	Miss	-	-	+14.3%
Sep 30, 2022Sep 22 Reported Dec 29, 2022Reported Dec 29	$-0.24	$-0.30	-	+21.13%	Beat	-	-	+14.3%
Jun 30, 2022Jun 22 Reported Aug 9, 2022Reported Aug 9	$-0.28	$-0.30	-	+6.67%	Beat	-	-	-3.7%
Mar 31, 2022Mar 22 Reported Jun 28, 2022Reported Jun 28	$-0.28	$-0.30	-	+6.04%	Beat	-	-	-3.7%
Dec 31, 2021Dec 21 Reported Mar 30, 2022Reported Mar 30	$-0.28	$-0.30	-	+5.31%	Beat	-	-	-27.3%
Sep 30, 2021Sep 21 Reported Dec 29, 2021Reported Dec 29	$-0.28	$-0.28	-	-0.61%	Miss	-	-	-600.0%
Jun 30, 2021Jun 21 Reported Sep 28, 2021Reported Sep 28	$-0.27	$-0.26	-	-3.05%	Miss	-	-	-35.0%
Mar 31, 2021Mar 21 Reported Jun 28, 2021Reported Jun 28	$-0.27	$-0.23	-	-18.42%	Miss	-	-	-50.0%
Dec 31, 2020Dec 20 Reported Mar 30, 2021Reported Mar 30	$-0.22	$-0.24	-	+9.95%	Beat	-	-	+4.3%
Sep 30, 2020Sep 20 Reported Nov 9, 2020Reported Nov 9	$-0.04	N/A	-	+81.82%	Beat	-	-	+98.2%
Jun 30, 2020Jun 20 Reported Aug 12, 2020Reported Aug 12	$-0.20	$-0.21	-	+4.76%	Beat	-	-	-122.2%
Mar 31, 2020Mar 20 Reported Jun 29, 2020Reported Jun 29	$-0.18	$-0.23	-	+21.74%	Beat	-	-	-100.0%
Dec 31, 2019Dec 19 Reported Mar 30, 2020Reported Mar 30	$-0.23	$-0.28	-	+17.86%	Beat	-	-	-9.5%
Sep 30, 2019Sep 19 Reported Dec 29, 2019Reported Dec 29	$-2.26	$-0.04	-	-5550.00%	Miss	-	-	-253.1%
Jun 30, 2019Jun 19 Reported Aug 7, 2019Reported Aug 7	$-0.09	$-0.05	-	-80.00%	Miss	-	-	-175.0%
Mar 31, 2019Mar 19 Reported May 6, 2019Reported May 6	$-0.09	N/A	-	+60.87%	Beat	-	-	+85.5%
Dec 31, 2018Dec 18 Reported Mar 30, 2019Reported Mar 30	$-0.21	N/A	-	+73.42%	Beat	-	-	+69.6%
Sep 30, 2018Sep 18 Reported Nov 7, 2018Reported Nov 7	$-0.64	$-0.21	-	-204.76%	Miss	-	-	-28.0%
Jun 30, 2018Jun 18 Reported Aug 8, 2018Reported Aug 8	$0.12	N/A	-	+120.34%	Beat	-	-	+120.3%
Mar 31, 2018Mar 18 Reported Jun 29, 2018Reported Jun 29	$-0.62	$-0.66	-	+6.06%	Beat	-	-	-72.2%
Dec 31, 2017Dec 17 Reported Mar 30, 2018Reported Mar 30	$-0.69	$-0.57	-	-21.05%	Miss	-	-	-43.7%
Sep 30, 2017Sep 17 Reported Nov 8, 2017Reported Nov 8	$-0.50	$-0.59	-	+15.25%	Beat	-	-	-
Jun 30, 2017Jun 17 Reported Aug 8, 2017Reported Aug 8	$-0.59	$-0.51	-	-15.69%	Miss	-	-	-
Mar 31, 2017Mar 17 Reported Jun 29, 2017Reported Jun 29	$-0.36	$-0.51	-	+29.41%	Beat	-	-	-
Dec 31, 2016Dec 16 Reported Mar 30, 2017Reported Mar 30	$-0.48	$-0.51	-	+5.88%	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	-4.76	EV/EBITDA	N/A
Price/FCF	-6.16x	FCF Yield	-16.24%
Profitability
Profit Margin	0.00%	Operating Margin	0.00%
ROE	-45.30%	ROIC	-43.52%
Financial Health
Debt/Equity	0.00x	Interest Coverage	N/A
Current Ratio	10.64x	Quick Ratio	10.64x
Trading Statistics
Beta	2.09	Avg Volume	393.35K
52-Week High	$43.66	52-Week Low	$15.93

Technical Indicators Dashboard

Moving Averages

SMA 10$24.85

SMA 20$27.42

SMA 50$33.10

SMA 200$27.44

EMA 10$24.91

EMA 20$27.21

EMA 50$30.70

EMA 200$28.74

MACD

Line: -2.91Signal: -2.68Hist: -0.24

ADX

ADX: 28.0+DI: 19.8-DI: 30.4

Aroon & PSAR

Aroon UpN/A

Aroon Down96.0

PSAR$28.71

Bollinger Bands

Upper Band$34.11

Lower Band$20.74

%B Position4875%(Upper)

Band Width0.24

RSI (14-Day)

Neutral

34.3

Momentum Oscillators

Stoch %K15.5

Stoch %D9.1

Williams %R-66.2

ROC (10d)-9.8%

Momentum-2.60

CCI (20d)-105.5

MFI (14d)45.1

Volatility Measures

ATR (14d)$2.26(9.4%)

StdDev (20d)3.34

Hist Vol78.5%(High)

Volume Flow

VWAP$23.57

OBV6.7M

AD Line-836.9K

CMF (20d)-0.239

Volume Metrics

Avg Vol (20d)412.5K

Vol Ratio1.4x

VWMA (20d)$28.36

Pivot Points

R3$24.22

R2$23.36

R1$22.77

Pivot Point$21.91

S1$21.32

S2$20.46

S3$19.87

Advanced Oscillators

TSI-40.80

Ultimate Osc30.1

KST-285.03

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$0	$0	$0	$0	$0	$0	$-925,000	$0	$925,000	$0	$0	$0
Cost of Revenue	$0	$0	$787,000	$0	$0	$0	$15.35M	$0	$0	$0	$12.18M	$0
Gross Profit	$0	$0	$-787,000	$0	$0	$0	$-15,347,000	$0	$925,000	$0	$-12,184,000	$0

Operating Expenses	$36.67M	$33.35M	$27.53M	$23.80M	$26.08M	$25.92M	$21.51M	$22.18M	$21.06M	$18.78M	$14.73M	$15.22M
R&D	$25.47M	$25.15M	$20.64M	$17.24M	$19.37M	$17.76M	$15.35M	$16.29M	$15.74M	$13.54M	$12.18M	$11.61M
SG&A	$11.20M	$8.20M	$6.89M	$6.56M	$6.71M	$8.16M	$6.17M	$5.89M	$5.32M	$5.24M	$2.55M	$3.61M
Operating Income	$-36,670,000	$-33,349,000	$-27,530,000	$-23,798,000	$-26,081,000	$-25,919,000	$-21,512,000	$-22,180,000	$-20,134,000	$-18,779,000	$-14,733,000	$-15,219,000

Interest Income	$2.05M	$2.26M	$2.67M	$2.74M	$2.93M	$3.21M	$2.27M	$1.84M	$2.04M	$2.32M	$781,000	$650,000
Interest Expense	$0	$0	$1,000	$1,000	$1,000	$2,000	$2,000	$3,000	$4,000	$3,000	$3,000	$4,000
Income Before Tax	$-34,631,000	$-30,934,000	$-23,226,000	$-21,102,000	$-23,228,000	$-22,647,000	$-19,084,000	$-20,360,000	$-18,636,000	$-17,064,000	$-13,972,000	$-14,577,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-34,488,000	$-30,934,000	$-24,735,000	$-20,953,000	$-22,016,000	$-22,647,000	$-19,514,000	$-20,217,000	$-18,492,000	$-16,921,000	$2.38M	$-14,577,000

EBITDA	$-36,201,000	$-32,715,000	$-25,612,000	$-23,880,000	$-26,861,000	$-26,836,000	$-21,513,000	$-22,080,000	$-20,176,000	$-19,002,000	$-14,027,000	$-15,544,000
EBIT	$-36,677,000	$-33,195,000	$-25,899,000	$-23,840,000	$-26,155,000	$-25,851,000	$-21,352,000	$-22,199,000	$-20,667,000	$-19,381,000	$-14,750,000	$-15,223,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about NGNE

News

Precision Trading with Neoleukin Therapeutics Inc. (NGNE) Risk Zones

This article analyzes Neoleukin Therapeutics Inc. (NGNE) with AI-generated trading strategies and risk zones. It highlights weak near and mid-term sentiment but a strong long-term outlook, providing specific entry...

Stock Traders Daily•Oct 6, 2026 7:28 AM ET10/6/26•Somewhat-Bearish

Technical Reactions to NGNE Trends in Macro Strategies

This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE) using AI models to develop distinct trading strategies. It highlights a strong near-term sentiment potentially leading to a long-term positive bias...

Stock Traders Daily•Aug 15, 2026 9:40 PM ET8/15/26•Bullish

(NGNE) Volatility Zones as Tactical Triggers

This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE), highlighting weak near-term sentiment but strong mid and long-term outlooks. It identifies a significant 73.1:1 risk-reward short setup and provides...

Stock Traders Daily•Jul 24, 2026 3:11 AM ET7/24/26•Somewhat-Bearish

NGNE Valuation and Fair Value

P/E: -4.8x
P/FCF: -6.2x
P/B: 2.5x

See GNG's fair value

NGNE Profitability: Margins, ROIC and FCF

Operating margin: 0.0%
Net margin: 0.0%
ROIC: -43.5%
ROE: -45.3%
FCF yield: -16.2%

NGNE Competitors

Company	Ticker
Cerus Corporation	CERS
Kamada	KMDA
National Research Corp	NRC
Oculis Holding AG Ordinary shares	OCS
Brainsway Ltd	BWAY
Alpha Teknova Inc	TKNO
Tilray Inc	TLRY
XOMA Corporation	XOMAO

Sector: Healthcare

NGNE Analyst Ratings

Consensus: Buy
Analysts: 9
Strong Buy: 0
Buy: 9
Hold: 0
Sell: 0
Strong Sell: 0

NGNE Bull Case vs Bear Case

Bull case

NGNE beat EPS estimates in 75.0% of its last 8 reported quarters.
100.0% of NGNE's analyst ratings are Buy or Strong Buy.

NGNE Earnings: Beat Rate and Next Report

Beat rate: 6 of 8 quarters (75.0%)
Average surprise: 3.5%
EPS estimate (fiscal period ending Sep 30, 2026): $-1.42
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 3 up, 3 down

Frequently Asked Questions About NGNE

Does NGNE pay dividends?

Neurogene Inc (NGNE) does not currently pay a regular dividend.

What is NGNE's market cap?

Neurogene Inc (NGNE) has a market capitalization of $443.85M with a current stock price of $23.95.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In